Physicochemical property trends of marketed prodrugs

Therapeutic Delivery

Volumn 4, Issue 2, 2013, Pages 225-237

  Landis, Margaret S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEMETACIN; ACETYLCYSTEINE; ADEFOVIR DIPIVOXIL; ALATROFLOXACIN; ALBENDAZOLE; AMIFOSTINE; AMPIROXICAM; AMRUBICIN; AMTOLMETIN GUACIL; BACAMPICILLIN; BALSALAZIDE; BAMBUTEROL; BITOLTEROL MESILATE; BOPINDOLOL; CANDESARTAN HEXETIL; CAPECITABINE; CARISOPRODOL; CEFOTIAM HEXETIL; CEFPODOXIME PROXETIL; CICLESONIDE; CINNOXICAM; CLOFIBRATE; CYCLOPHOSPHAMIDE; DELAPRIL; DIACEREIN; DROXICAM; EBASTINE; ENALAPRIL; PRODRUG; UNINDEXED DRUG;

AQUEOUS SOLUBILITY; COMPUTER SIMULATION; DATA BASE; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SOLUBILITY;

EID: 84872893452     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.150     Document Type: Review

References (107)

1. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley J. Prodrugs: Challenges and Rewards. Springer Inc., New York, NY, USA (2007).
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
3. Stella VJ. Prodrugs as therapeutics. Expert. Opin. Ther. Patents 14(3), 277-280 (2004). (Pubitemid 38380266)
4. Chávez-Piña AE, Favari L, Castañeda-Hernández G. Pharmacokinetics of acemetacin and its active metabolite indomethacin in rats during acute hepatic damage and liver regeneration. Annals Hepatology 8(2), 141-147 (2009).
5. Cacciatore I, Cornacchia C, Pinnen F, Mollica A, Di Stefano A. Prodrug approach for increasing cellular glutathione levels. Molecules 15, 1242-1264 (2010).
6. Dando TM, Plosker GL. Adefovir dipivoxil: a review of its use in chronic hepatitis. Drugs 63(20), 2215-2234 (2003). (Pubitemid 37289922)
7. Rautio J. Methods and principles in medicinal chemistry. In: Prodrugs and Targeted Delivery: Towards Better ADME Properties. Mannhold R, Kubinyi H, Folkers G (Eds).Wiley-VCH, Weinhiem, Germany (2011).
8. Castro N, Marquez-Caraveo C, Brundage RC et al. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int. J. Clin. Pharm. Ther. 47(11), 679-685 (2009).
9. Jung H, Medina L, Garcia L, Fuentes I, Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J. Pharm. Pharmacol. 50, 43-48 (1998). (Pubitemid 28052519)
10. Rajewski RA. Case study: amifostine: (Ethyol®). In: Challenges and Rewards Part 1. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley J (Eds). Springer Inc, New York, NY, USA (2007).
11. Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, Weissman A. Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions 39, 157-165 (1993). (Pubitemid 23349825)
12. Hamada A, Okamoto I, Matsunaga Y et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients: preliminary results. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings, 23(16S Part I of II) (2005).
13. Pisano C, Grandi D, Morini G et al. Gastrosparing effect of new antiflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Digest. Dis. Sci. 44(4), 713-724 (1999). (Pubitemid 29186314)
14. Tubaro E, Belogi L, Mezzadri CM. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. Eur. J. Pharm. 387, 233-244 (2000). (Pubitemid 30067821)
15. Entin-Meer M, Rephaeli A, Yang X, Nudelman A, Haas-Kogan DA. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Lett. 253(2), 205-214 (2007). (Pubitemid 47017535)
16. Sjovall J, Magni L, Vinnars E. Bioavailability of bacampicillin and talampicillin, two oral prodrugs of ampicillin. Antimicrob. Agents Chemother. 20(6), 837-838 (1981). (Pubitemid 12188205)
17. Kamada A. Pharmacokinetics and pharmacodynamics of bambuteroll, a long-acting bronchodialator prodrug of terbutaline, in young and elderly patients with asthma. Pediatrics 94, 264 (1994).
18. Kelly HW. New beta 2-adrenergic agonist aerosols. Clin. Pharm. 4(4), 393-403 (1985). (Pubitemid 15234453)
19. Aellig WH. Pharmacological experiments in healthy volunteers with bopindolol, a long-lasting beta-adrenoceptor blocking drug with partial agonist activity. Br. J. Clin. Pharmac. 19, 775-781 (1985). (Pubitemid 15232145)
20. Husain A, Azim S, Mitra M, Bhasin PS. A review on candesartan: pharmacological and pharmaceutical profile. J. Am. Pharm. Sci. 1(10), 12-17 (2011).
21. Shimma N. Case study: capecitabine: a prodrug of 5-fluorouracil. In: Prodrugs: Biotechnology Pharamceutical Aspects Volume 5. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley J (Eds.). Springer, New York, NY, USA, 1173-1183 (2007).
22. Miwa M, Ura M, Nishada M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluoro-uracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34(8), 1274-1281 (1998). (Pubitemid 28342121)
23. Berger FM, Kletzkin M, Ludwig BL, Margolin S. The History, chemistry and pharmacology of carisoprodol. Ann. NY Acad. Sci. 90-107 (1960).
24. Klaubert DH, Essery JM, Barrett JF. New cephalosporins in development pipeline. Expert. Opin. Invest. Drugs 3(2), 133-144 (1994).
25. Fujimoto M. Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients. Int. J. Antimicrob. Agents 18, 489-494 (2001). (Pubitemid 33065663)
26. Saito A, Hiraga Y, Watanabe A et al. Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. J. Int. Med. Res. 32, 590-607 (2004). (Pubitemid 39561763)
27. Fuchs T. Case study: cefditoren pivoxil: an oral prodrug of cefditoren. In: Prodrugs: Biotechnology Pharamceutical Aspects. Springer, New York, NY, USA, 1185-1194 (2007).
28. Chachaty E, Rosembaum M, Tancrede C, Andremont A. Effect of oral cefotiam hexetil (SCE2174) on faecal bacteria in human volunteers. Microb. Ecol. Health Dis. 4, 89-94 (1991).
29. Testa B, Mayer JM. The hydrolysis of carboxylic acid ester prodrugs. In: Hydrolysis in Drug and Prodrug Metabolism. Testa B, Mayer, JM (Eds). Wiley-VCH, Weinhiem, Germany 419-534 (2003).
30. Wichitnithad W, Nimmannit U, Wacharasindhu S, Rojsitthisak P. Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment. Molecules 16, 1888-1900 (2011).
31. Wong GW. Ciclesonide: a new inhaled corticosteroid. Drug Rev. 12(1), 25-26 (2007).
32. Jayaselli J, Cheemala JM, Rani G, Pal S. Derivatization of enolic OH of piroxicam: a comparative study on esters and sulfonates. J. Braz. Chem. Soc. 19(3), 509-515 (2008).
33. Morozowich W, Karnes HA. Case study: clindamycin 2-phosphate, a prodrug of clindamycin. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Springer, New York, NY, USA, 1207-1219 (2007).
34. Miller DB, Spence JD. Clinical Pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokint 34(2), 155-162 (1998). (Pubitemid 28077673)
35. Jain M, Fan J, Baturay NZ, Kwon C-H. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide- resistant tumor cell lines. J. Med. Chem. 47, 3843-3852 (2004). (Pubitemid 38900349)
36. Mollee P, Arthur C, Hughes T et al. Interferon-a-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Ann. Oncology, 15, 1810-1815 (2004). (Pubitemid 40012248)
37. Salvetti A. Newer ACE inhibitors a look at the future. Drugs 40(6), 800-828 (1990). (Pubitemid 120032432)
38. Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: a new symptomatic slow acting drug for osteoarthritis. J. Med Ed. Res. 8(3), 173-175 (2006). (Pubitemid 44842537)
39. McConnell SA, Nafziger AN, Amsden GW. Lack of effect of dirithromycon on theophylline pharmacokinetics in healthy volunteers. J. Antimicrob. Chemother. 43, 733-736 (1999). (Pubitemid 29231704)
40. Nishiyama S, Yoshikawa M, Yamaguchi I. An orally effective peripheral dopamine prodrug: docarpamine (TA-870). Cardiovasc. Drug Rev. 10(1), 101-116 (1992).
41. Noveck RJ, Preston RA, Swan SK. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment. Clin. Pharmacokint. 46(6), 525-534 (2007). (Pubitemid 46827861)
42. Dhareshwar SS. Case study: enalapril: a prodrug of enalaprilat. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds.). Springer, New York, NY, USA 1221-1229 (2007).
43. Murthuraman A. Erdosteine therapy for renal failure: current prospectives. Nephro-Urol. Mon. 4(3), 587-588 (2012).
44. Steffansen B, Bundgaard H. Erythromycin prodrugs: kinetics of hydrolysis of erythromycin and various erythromycin 2́-esters in aqueous solution and human plasma Int. J. Pharm., 56, 159-168 (1989). (Pubitemid 19283758)
45. Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung 43, 1014-1017 (1993). (Pubitemid 23274365)
46. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59, 677-694 (2007). (Pubitemid 47285410)
47. Witterland AH, Koks CH, Beijnen JH. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm. World Sci. 18(5), 163-170 (1996). (Pubitemid 26364524)
48. Gudmundsson OS, Antman M. Case study: famciclovir: a prodrug of penciclovir. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds.). Springer, New York, NY, USA, 1231-1239 (2007).
49. Dickinson PA, Taylor G. Route dependent pulmonary first-pass metabolism of a series of biphenylacetic acid esters in rats. Eur. J. Pharm. Sci. 6, 11-18 (1998). (Pubitemid 28035220)
50. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr. Med. Chem. 16, 4481-4489 (2009).
51. Karasawa F, Ehata T, Okuda T, Satoh T. Propofol injection pain is not alleviated by pretreatment with flurbiprofen axetil, a prodrug of a nonsteroidal antiinflammatory drug. J. Anesthesia 14(3), 135-137 (2000).
52. Ouyang H. Case study: fosamprenavir: a prodrug of amprenavir. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1241-1249 (2007).
53. Bentley A, Butters M, Green SP et al. The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org. Process Res. Dev. 6, 109-112 (2002).
54. Petrillo EW. Case study: fosinopril. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1251-1258 (2007).
55. Stella VJ. Case study: fosphenytoin: a prodrug of phenytoin. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1259-1267 (2007).
56. Schleyer E, Braess J, Ramsauer B et al. Pharmacokinetics of Ara-CMP-Stearate (YNK01): Phase I study of the oral Ara-C derivative. Leukemia 9(6), 1085-1090 (1995).
57. Bolser DC. Cough suppressant and pharmacologic protussive therapy : ACCP evidence-based clinical practice guidelines. Chest 129(Suppl 1), 238S-249S (2006). (Pubitemid 43265228)
58. Gubert S, Palacin C, Sacistan A, Ortiz JA. synthesis and oral absorption of hetacillin and hetamoxicillin labile esters. Chem. Pharm. Bull 35(6), 2366-2372 (1987). (Pubitemid 17110561)
59. Fleisher D, Bong R, Stewart BH. Improved oral drug delivery: solubility limitations of prodrugs. Adv. Drug Deliv. Rev. 19, 115-130 (1996). (Pubitemid 26192965)
60. Hageman MJ, Morozowich W. Case study: irinotecan (CPT-11), a water-soluble prodrug of SN-38. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1269-1279 (2007).
61. Bandyopadhyay P. Case study: latanoprost: isopropylester of a prostaglandin F2α analog. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1281-1288 (2007).
62. Hauser RA. Levodopa: past, present, and future. Eur. Neurol. 62, 1-8 (2009).
63. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin. Pharmacother. 9(9), 1565-1574 (2008). (Pubitemid 352005916)
64. Sjolin-Forsberg G, Hermansson J. Comparative bioavailability of tetracycline and lymecycline. Br. J. Clin. Pharmacol. 18(4), 529-533 (1984). (Pubitemid 14009945)
65. Toutain PL, Bousquet-Melou A. Plasma terminal half life. J. Vet. Pharmacol. Therap. 27, 427-439 (2004).
66. Daley-Yates PT, Gregory AJ, Brooks CD. Pharmacokinetics and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Br. J. Clin. Pharmacol. 43, 593-601 (1997). (Pubitemid 27283568)
67. Al-Habet SM, Rogers HJ. Methylprednisolone pharmacokinetics after intraveneous and oral administration. Br. J. Clin. Pharmacol. 27, 285-290 (1989). (Pubitemid 19097436)
68. Fossati A, Vimercati MG, Bozzi M, Passarotti C, Bandi GL, Formenti A. Effects of metoxibutropate, ibuprofen and guaiacol on the gastrointestinal system. Int. J. Tissue React. 13(1), 45-50 (1991).
69. Vaidyanathan S, Soni B, Hughes P. Midodrine: insidious development of urologic adverse effects in patients with spinal cord injury: a report of 2 cases. Adv. Ther. 24(4), 712-720 (2007). (Pubitemid 351612245)
70. Wang B, Siahaan TJ, Soltero RA. Drug Delivery: Principles and Applications. John wiley and Sons, New York, NY, USA (2005).
71. Liederer BM. Case study: moexipril hydrochloride: a prodrug of moexiprilat. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1289-1297 (2007).
72. Fulton B, Markham A. Mycophenolate mefetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51(2), 278-298 (1996).
73. Kisor DF, Plunkett W, Kurtzberg J et al. Pharmacokinetics of nelarabine and 9-beta-d-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. 18(5), 995-1003 (2000). (Pubitemid 30123775)
74. John SR, Chakrabarti M, Chakrabarti A. Nepafenac. Kerala Journal of Ophthalmology, XXI(3), 285-288 (2009).
75. Liederer BM. Case study: olmesartan medoxomil: a prodrug of olmesartan. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1305-1312 (2007).
76. Hemenway JN. Case study: omeprazole (prilosec). In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1313-1321 (2007).
77. Eisenberg EJ. Case study: oseltamivir: an orally bioavailable ester prodrug of oseltamivir carboxylate. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1323-1334 (2007).
78. Teagarden DL, Nema S. Case study: parecoxib: a prodrug of valdecoxib. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA, 1335-1346 (2007).
79. Agersborg HP, Batchelor A, Cambridge GW, Rule AW. The Pharmacology of penamecillin. Br. J. Pharmacol. 26, 649-655 (1966).
80. Curran MP, McCormack PL, Simpson D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs 66(2), 235-255 (2006). (Pubitemid 43216238)
81. Calogeropoulou T, Detsi A, Lekkas E, Koufaki M. Strategies in the design of prodrugs of anti-HIV agents. Curr. Top. Med. Chem. 3, 1467-1495 (2003).
82. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int. J. Antimicrob. Agents 22(Suppl 2), 73-78 (2003).
83. Silverman RB. The Organic Chemistry of Drug Design and Drug Action (Academic Press, 2004).
84. Keam SJ, Perry CM. Prulifloxacin. Drugs 64(19), 2221-2234 (2004). (Pubitemid 39382210)
85. Hao R, De Vera M, Resurreccion E. Racecadotril in the treament of acute diarrhea in chlidren: a meta-analysis. PIDSP J. 11(2), 19-32 (2010).
86. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin. Pharmacokint. 26(1), 7-15 (1994). (Pubitemid 24029184)
87. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J. Antimicrob. Chemother. 41 (Suppl. B), 47-50 (1998). (Pubitemid 28152223)
88. Smyth RD, Pfeffer M, Van Harken DR, Cohen A, Hottendorf GH. Human pharmacokinetics and disposition of sarmoxcillin, a lipophilic amoxicillin prodrug. J. Antimicrob. Chemother. 19(6), 1004-1012 (1981). (Pubitemid 11035886)
89. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Met. Dispos. 18(2), 138-145 (1990). (Pubitemid 20107705)
90. Duggan DE. Suldinac: therapeutic implications of the prodrug/ pharmacophore equilibrium. Drug Met Rev, 12(2), 325-337 (1981). (Pubitemid 12072724)
91. Leigh DA, Reeves DS. Talampicillin: a new derivative of ampicillin. Br. Med. J. 1378-1380 (1976).
92. Guenther LC. Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging. Skin Ther. Lett. 7(3), 1-4 (2002).
93. Chan OH, Schmid HL, Stilgenbauer LA, Howson W, Horwell DC, Stewart BH. Evaluation of a targeted prodrug strategy to enhance oral absoprtion of poorly water-soluble compounds. Pharm. Res. 15(7), 1012-1018 (1998). (Pubitemid 28356916)
94. Puchler K, Sierakowski B, Roots I. Single dose and steady state pjarmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br. J. Pharmacol. 46, 363-367 (1998).
95. LarocheIle P, Du Souich P, Bolte E, Lelorier J, Goyer R. Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectaland intranasal application. Clin. Pharm. Ther. 343-350 (1983). (Pubitemid 13089525)
96. Antman MD, Gudmundsson OS. Case study: valacyclovir: a prodrug of acyclovir. In: Prodrugs, Challenges and Rewards Part 1 and Part 2. Stella VJ, Borchardt RT, Hageman MJ et al (Eds). Springer, New York, NY, USA,1369-1376 (2007).
97. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89(6), 781-789 (2000).
98. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 17(2), 115-133 (1999). (Pubitemid 29485360)
99. Wieser ME, Coplen TB. Atomic weights of the elements. Pure Appl. Chem. 75(8), 1107-1122 (2003).
100. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its applications to the prediction of drug transport properties. J. Med. Chem. 43, 3714-3717 (2000).
101. Obach RS, Lombardo F. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J. Med. Chem. 49(7), 2262-2267 (2006).
102. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clincal applications. Nat. Rev. Drug Discov. 7, 255-270 (2008).
103. Guarino VR. Modulating solubility through prodrugs for oral and IV Drug delivery. In: Prodrugs and Targeted Delivery: Towards Better ADME Properties. Rautio J (Ed.). Wiley-VCH, Weinheim, Germany, 81-109 (2001).
104. Notari RE. Pharmacokinetic aspects of prodrug design and evaluation. In: Design of Prodrugs. Bundgaard H (Ed.). Elsevier Science Publishers Biomedical Division, Amsterdam, The Netherlands (1985).
105. Jusko WJ, Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Met. Revs. 5(1), 43-140 (1976).
106. Dahan A, Khamis M, Agbaria R, Karaman R. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opin. Drug Deliv. 9(8), 1001-1013 (2012).
107. Karaman R. The future of prodrugs designed by computational chemistry. Drug Designing: Open Access 1(1), 1-3 (2012